Member Info for DRB83

Is there visibility of any of the other NHS trusts/hospitals buying activities? I'm sure you're already on with it. Good work

Helx, yep that must be it. Can't think of any other reason. That's probably why Manuel Pellegrini left Man City. Oh dear

Is that all you know about the situation? There's at least 20 reasons why someone would leave a position. Some negative for the business, some negative for the person but also some positive for the business and some positive for the person.

Without more information there's just too many reasons to arrive at any accurate conclusion so why stress about it.

You could read into now as a negative and an indicator that the business is failing and sell up, only for the business update to come out and tell you that you read it all wrong and now your left buying back in at a higher price. Of course you may get it right and you pat yourself on the back.

Just not enough information for it to effect your decision making imo.

I can sell all but I can also buy 5000000 at 0.63. they'd have to have 5000000 spare to immediately fill my buy order wouldn't they?

If there is a large buy order I'm assuming it is at 0.6-0.65 as the MM's are currently buying at 0.55-0.57.

If a large buyer is there then surely there'd be a massive disconnect between buys and sells over the last couple of weeks. Should be way more sells than buys showing. For a buyer to be there this long we must be talking 50m shares. Also the MM's clearly not doing their job if it takes weeks to fill an order.

To be fair, the bigger any company gets the more changes you'll find at the top and throughout. Its impossible to read accurately into what it means unless you personally know him and get the real reason from the horse's mouth. So on that basis, best to not read anything into at all.

It's a good sign. H2 revenue is £9m. That's £1.5m per month. NHS Devon just spent at least £100k in May. Could be several smaller orders <£25k too. So one small part of one of our customers placed orders for 7% of our monthly forecast. When you factor in that the UK represents less than half of our total business and that the H2 revenue will be stacked mostly in Q4 then seeing these orders is very encouraging imo

Now it's 14 trading days with no Tobin buy. Has he ran out of money or is there another reason. It seems odd that he would just decide to stop givennhe can now get them 60% cheaper than before. Not a bad summer sale really.

Don't agree Ping

The market will anticipate the income 4-6 months before. The mining license, off take agreements and funding will be checkpoints imo. Increasing the resource should also be received well by the market. Lots of news to come.

I'm more interested in what the iron ore price will be in 6-9 months time. Palladium, Silver even further out.

Yes, we pretty much have 100% on everything except Elephant which is now 80%.

We'll convert the Mopani decommissioned refinery into a fully functioning one that will also be able to process Cobalt from Elephant. The cobalt at Elephant is 0.08%. the Cobalt at Roan is 0.05% which is still substantial given its high value.

Steve, I suspect equipment has been reserved with delivery date to be confirmed. If we're not digging until Mar/Apr it doesn't make much sense to have cabins in place now. 7-8 months away. Once they are onsite they are incurring costs so get them onsite a month or so before.

Jonah, A few extracts from previous rns's that may help shed some light.

During 2020, Jubilee entered into joint venture agreements to secure rights to process over 300 million tonnes of copper and cobalt containing tailings in Zambia. The copper and cobalt tailings are located in three central locations named Project Roan, Project Lechwe and Project Elephant.

From an earlier RNS, and part of the 300m mentioned above:

The Agreements secure the rights to an additional approximate 115 million tonnes of copper containing tailings located within a 50 km radius from Jubilee's Project Elephant and within the Kitwe area

The close proximity of all of the projects offers the potential to integrate components of the processing facilities, which could offer significant capital savings

The Tailings have been previously drilled and sampled to confirm both content and size containing on average 0.3% copper and 0.05% cobalt

Also noticed this:

Under the terms of the Agreements, Braemore secures the exclusive right to gain free unrestricted access to the tailings resources and to uplift and process the tailings to recover copper and cobalt for on-sale into the market. Braemore is appointed as the exclusive operator and solution provider to bring to account the Tailings. In recognition of this right afforded to Braemore, the Tailings Partners are entitled to a future earnings share from the processing of their respective tailings by Braemore ranging from 17% to 30%. Such earnings share includes a capital charge allocated to each Tailings Partner by Braemore in respect of the capital expended by Braemore for the implementation and commissioning of the processing facility for the respective Tailings.

Seis, Not sure if you'd factored this earnings share in to your copper calculations.

So in summary, it looks as though the tailings are dotted about the 3 sites but as the projects are all relatively close by there is no need to immediately commission additional Cobalt systems. In the future that may change.

Huey, from the strategy RNS:

Lab21 Healthcare and Microgen Bioproducts

As communicated in January 2022, the Company commenced a strategic review of its Lab21 Healthcare and Microgen Bioproducts businesses, which has now concluded. As outlined in the review, the costs associated with updating the existing portfolios in these businesses to comply with IVDR and ISO regulations are prohibitive versus the sales opportunity it presents.



Therefore, Novacyt is proposing to discontinue both businesses, which will be treated as discontinued under IFRS 5 for 2022 accounting. The estimated sales impact of this decision is circa £2.9m in 2022, with a gross margin reduction of £1.45m, which is expected to be fully offset by cost savings. A cash restructuring charge of circa £0.5m is expected, however, this should be fully financed from in-year savings and the release of working capital to make the closure of the businesses cash neutral in 2022.

From trading update RNS:

As announced at the time of the full year 2021 results, following a strategic review, Novacyt is discontinuing its Lab21 Healthcare and Microgen Bioproducts businesses. Following a further review based on the faster than expected decline in COVID-19 revenue, the Company is taking steps to further rationalise its cost base, targeting an additional reduction in operating costs of £2.4m this year and a one-off cash restructuring charge of circa £0.8m.

I don't think you can claim the redundancies as your predictions when they've be telling us since April.

We've gone from £300m revenues to £25m so unfortunately redundancies had to happen. It may not be great for the employees but the restructuring is essential for ncyt. We build from a new baseline.

One for discussion. I was perusing the ABDX board this morning and stumbled upon this:

Q: I was curious if the FDA has any recommendations or advice for saliva-based antigen home tests?

A: So we've seen quite a bit of attempts at saliva-based antigen tests. I don't know exactly why it's been such a challenge. You know, there are a lot of advantages if it would work, but it may be that there's a concentration that's needed, such as with a molecular test.
So some of the molecular tests have not worked quite well in saliva, but that may be due to the concentration effect in extraction. So if you want to attempt it, you would just follow the recommendations, if you want, for antigen test validation. The comparator for saliva would be a nasopharyngeal swab using a high sensitivity molecular central lab test.
I would double check with the FDA before using a comparator test to make sure that it's high sensitivity enough. And then thirty positives and thirty negatives if you're going for symptomatic individuals.
We have recommended to others that want to pursue saliva. If this is a new test, we would recommend that you also consider as a backup and anterior nares swab. So that if you should have any issues with saliva, at least you have anterior nares.

https://www.fda.gov/media/160670/download

Seems it is a great challenge for all. It would be highly impressive if ncyt have found a way to make it work. That could be very significant and not just for covid.

Time to monetise our world class bioinformatics assets.

B2. I recall recently another of our US distributors selling for $8 per test. Are ncyt finally recognising the need to sacrifice a little margin to grow market share. Let's hope so.

Thanks seis. Good to see it mapped out. I've gone a little less conservative on the Cobalt and turning out $120m earnings for FY23. It would be interesting to see what you get for FY24 assuming the rest of the copper comes online by end of CY23. Elephant also has Cobalt. I forecast another step up in earnings.

Steve, correct they could but a price increase would have to be 2 fold. First to pass on the increase in energy and food costs and then second to increase margins. With macro economics as they are it's not a great time to be forced into putting prices up.

Mortgage payments going up
Energy bills unfathomable
Fuel costs rediculous.
Food prices sky high

It certainly will be interesting to see the next results.

Unfortunately, no one here will be able to confidently answer that question. H2 was Jan to Dec so fuel costs would have a lot to do with it.

My question would be. Why do we still transport it I'm from the EL when transport costs are so high. Surely we have enough Western Limb material or is it a case of meeting a contractual clause?